BioSpace News Archive

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2020 on Thursday, November 26, 2020. A presentation on the Company’s third quarter and year-to-date 2020 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange und

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that members of management will participate in A.G.P.’s Virtual Healthcare Symposium on Thursday, November 19 th , 2020. The event will consist of 1-on-1 virtual investor meetings. Investors attending the conference virtually who are interested in meeting with C

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, today announced the addition of Eriks Rozners, Ph.D. and Randy Davis, MBA to its scientific advisory board (SAB). Dr. Rozners, an expert in nucleic acid biochemistry, and Mr. Davis, a biotechnology industry veteran, bring extensive experience to NeuBase. “We are thrilled to w

Lacutamab granted PRIME designation inSézary Syndrome by the European Medicines Agency

Endometrial cancer starts in the inner lining of the uterus, and the cells grow out of control. It usually affect women past menopause, and the risk increases above the age of 40.

The increasing cases of chronic anemia and the need to reduce chronic iron overload in such patients stands as the key factor boosting the global exjade market growth.

Drug development and discovery is a lengthy, intense, and interdisciplinary endeavor. It is mostly portrayed as a consecutive and linear process that starts with lead and target discovery, followed by lead optimization and pre-clinical in-vivo and in-vitro studies to define if such compounds fulfill a number of pre-set criteria to start clinical development.

Growing geriatric population in several parts of the world who require frequent visits to hospitals, clinics is a primary factor fuelling the health insurance exchange market.

A phase II study of NBTXR3 activated by radiation and combined with pembrolizumab for patients with recurrent or metastatic head and neck squamous cell carcinoma with limited PD-L1 expression or refractory to PD-1 blockade

Clinical Laserthermia Systems AB, announced the clinical study performed in collaboration with Toronto General Hospital, Canada, and Dr. Sangeet Ghai now is recruiting patients for the extended Phase II trial where 30 additional patients, with localized low or intermediate risk prostate cancer, will be treated with MRI-guided focal laser ablation.